Skip to main content

Table 2 Comparison in clinical characteristics between patients with plaque regression and progression

From: Relationship between Advanced Glycation End Products and Plaque Progression in Patients with Acute Coronary Syndrome: The JAPAN-ACS Sub-study

  Regression Progression P-value
N=180 N=28
Age (yrs) 62.4 ± 10.6 65.8 ± 13.6 0.1
Male 142 (78.9) 24 (85.7) 0.4
BMI (kg/m2) 24.3 ± 3.5 23.6 ± 2.5 0.2
Diabetes mellitus 48 (26.7) 14 (50.0) 0.016
Hypertension 107 (59.4) 20 (71.4) 0.2
Smoking 85 (47.2) 11 (39.3) 0.4
History of prior PCI 12 (6.7) 1 (3.6) 0.5
Type of ACS    0.3
STEMI 113 (62.8) 21 (75.0)
NSTEMI 26 (14.4) 4 (14.3)
UAP 41 (22.8) 3 (10.7)
Culprit Vessel    0.1
RCA 56 (31.1) 14 (50.0)
LAD 99 (55.0) 13 (46.4)
LCX 24 (13.3) 1 (3.6)
LMT 1 (0.6) 0 (0)
Type of stent    0.6
BMS 120 (66.7) 19 (67.9)  
DES 57 (31.7) 9 (32.1)  
Other than Stent (POBA) 3 (1.7) 0 (0)  
Analysis Segment    0.6
Proximal to target site 124 (68.9) 18 (64.3)  
Distal to target site 56 (31.1) 10 (35.7)  
Use of pitavastatin 96 (53.3) 14 (50.0) 0.7
  1. BMI, body mass index; PCI, percutaneous coronary intervention; ACS, acute coronary syndrome; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UAP, unstable angina pectoris; RCA, right coronary artery; LAD, left anterior descending artery; LCX, left circumflex branch; LMT, left main trunk; BMS, bare-metal stent; DES, drug-eluting stent; POBA, plain old balloon angioplasty.
  2. Data are expressed in numbers (percentage), unless otherwise specified. Age and BMI are presented as the mean ± SD. * < 0.05 vs. patients with regression.